Overview

A Study of GFS101A in Combination With Toripalimab in Patients With Advanced Solid Tumors

Status:
Not yet recruiting
Trial end date:
2025-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety/tolerability, pharmacokinetics, and efficacy of GFS101A in combination with Toripalimab in patients with advanced solid tumors.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Zhejiang Genfleet Therapeutics Co., Ltd.